Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Jenny M Reimer"'
Autor:
Francisco J. Martinez, Michael White, Micheline Guillotte-Blisnick, Christèle Huon, Alix Boucharlat, Fabrice Agou, Patrick England, Jean Popovici, Mimi M. Hou, Sarah E. Silk, Jordan R. Barrett, Carolyn M. Nielsen, Jenny M. Reimer, Paushali Mukherjee, Virander S. Chauhan, Angela M. Minassian, Simon J. Draper, Chetan E. Chitnis
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-11 (2024)
Abstract The receptor-binding domain, region II, of the Plasmodium vivax Duffy binding protein (PvDBPII) binds the Duffy antigen on the reticulocyte surface to mediate invasion. A heterologous vaccine challenge trial recently showed that a delayed do
Externí odkaz:
https://doaj.org/article/4ef9c0cbceda4b979429052cf23a7f55
Autor:
Jenny M Reimer, Karin H Karlsson, Karin Lövgren-Bengtsson, Sofia E Magnusson, Alexis Fuentes, Linda Stertman
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e41451 (2012)
Saponin-based adjuvants are widely used to enhance humoral and cellular immune responses towards vaccine antigens, although it is not yet completely known how they mediate their stimulatory effects. The aim of this study was to elucidate the mechanis
Externí odkaz:
https://doaj.org/article/7cf6222943d34672af1d6b8401ea30de
Autor:
Jeanette Grundström, Jenny M Reimer, Sofia E Magnusson, Gunnar Nilsson, Sara Wernersson, Lars Hellman
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e48308 (2012)
Basophils are blood cells of low abundance associated with allergy, inflammation and parasite infections. To study the transcriptome of mature circulating basophils cells were purified from buffy coats by density gradient centrifugations and two-step
Externí odkaz:
https://doaj.org/article/fd67e37d233e46a4b459d7ab06930e4b
Autor:
Francisco J. Martinez, Micheline Guillotte-Blisnick, Christèle Huon, Patrick England, Jean Popovici, Hélène Laude, Laurence Arowas, Marie-Noëlle Ungeheuer, Jenny M. Reimer, Darrick Carter, Steve Reed, Paushali Mukherjee, Virander S. Chauhan, Chetan E. Chitnis
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract The invasion of reticulocytes by Plasmodium vivax merozoites is dependent on the interaction of the Plasmodium vivax Duffy Binding Protein (PvDBP) with the Duffy antigen receptor for chemokines (DARC). The N-terminal cysteine-rich region II
Externí odkaz:
https://doaj.org/article/117c10d890b642bb92113492f4b97387
Autor:
Susheel K. Singh, Jordan Plieskatt, Bishwanath K. Chourasia, Vandana Singh, Karin Lövgren Bengtsson, Jenny M. Reimer, Renate C. van Daalen, Karina Teelen, Marga van de Vegte-Bolmer, Geert-Jan van Gemert, Matthijs M. Jore, Michael Theisen
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
Abstract The Plasmodium falciparum Pfs230 and Pfs48/45 proteins are leading candidates for a malaria transmission-blocking vaccine (TBV). Previously, we showed that a Pfs230–Pfs48/45 fusion protein elicits higher levels of functional antibodies tha
Externí odkaz:
https://doaj.org/article/d23619f475cb4d5dbe3391e5cc32c116
Autor:
Susheel K. Singh, Jordan Plieskatt, Bishwanath K. Chourasia, Amanda Fabra-García, Asier Garcia-Senosiain, Vandana Singh, Karin Lövgren Bengtsson, Jenny M. Reimer, Robert Sauerwein, Matthijs M. Jore, Michael Theisen
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
The cysteine-rich Pfs48/45 protein, a Plasmodium falciparum sexual stage surface protein, has been advancing as a candidate antigen for a transmission-blocking vaccine (TBV) for malaria. However, Pfs48/45 contains multiple disulfide bonds, that are c
Externí odkaz:
https://doaj.org/article/abac308fce534339b9649af5cb94636e
Autor:
Mimi M. Hou, Jordan R. Barrett, Yrene Themistocleous, Thomas A. Rawlinson, Ababacar Diouf, Francisco J. Martinez, Carolyn M. Nielsen, Amelia M. Lias, Lloyd D. W. King, Nick J. Edwards, Nicola M. Greenwood, Lucy Kingham, Ian D. Poulton, Baktash Khozoee, Cyndi Goh, Dylan J. Mac Lochlainn, Jo Salkeld, Micheline Guilotte-Blisnick, Christèle Huon, Franziska Mohring, Jenny M. Reimer, Virander S. Chauhan, Paushali Mukherjee, Sumi Biswas, Iona J. Taylor, Alison M. Lawrie, Jee-Sun Cho, Fay L. Nugent, Carole A. Long, Robert W. Moon, Kazutoyo Miura, Sarah E. Silk, Chetan E. Chitnis, Angela M. Minassian, Simon J. Draper
BackgroundThere are no licensed vaccines against Plasmodium vivax, the most common cause of malaria outside of Africa.MethodsWe conducted two Phase I/IIa clinical trials to assess the safety, immunogenicity and efficacy of two vaccines targeting regi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::364b22e40ad1268e8e4f2556fbede97b
https://hal-pasteur.archives-ouvertes.fr/pasteur-04117002
https://hal-pasteur.archives-ouvertes.fr/pasteur-04117002
Autor:
Mimi M, Hou, Jordan R, Barrett, Yrene, Themistocleous, Thomas A, Rawlinson, Ababacar, Diouf, Francisco J, Martinez, Carolyn M, Nielsen, Amelia M, Lias, Lloyd D W, King, Nick J, Edwards, Nicola M, Greenwood, Lucy, Kingham, Ian D, Poulton, Baktash, Khozoee, Cyndi, Goh, Dylan J, Mac Lochlainn, Jo, Salkeld, Micheline, Guilotte-Blisnick, Christèle, Huon, Franziska, Mohring, Jenny M, Reimer, Virander S, Chauhan, Paushali, Mukherjee, Sumi, Biswas, Iona J, Taylor, Alison M, Lawrie, Jee-Sun, Cho, Fay L, Nugent, Carole A, Long, Robert W, Moon, Kazutoyo, Miura, Sarah E, Silk, Chetan E, Chitnis, Angela M, Minassian, Simon J, Draper
Publikováno v:
medRxiv : the preprint server for health sciences.
There are no licensed vaccines againstWe conducted two Phase I/IIa clinical trials to assess the safety, immunogenicity and efficacy of two vaccines targeting region II ofThirty-two volunteers were enrolled and vaccinated (n=16 for each vaccine). No
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::af9a53b92d9028ac090fcdc36e9f1a39
https://pubmed.ncbi.nlm.nih.gov/35664997
https://pubmed.ncbi.nlm.nih.gov/35664997
Autor:
Florence Ouedraogo, Reshma Kailath, Amy Flaxman, Andres Noe, Rachidatou Soma, Fernando Ramos Lopez, Katie J. Ewer, Eli Rouamba, Umesh Shaligram, Jenny M. Reimer, Toussaint Rouamba, Federica Cappuccini, Ousmane Traore, Athanase M Some, Prisca Yameogo, Matthew Cairns, M Datoo, Daniel Valia, Benedict O. Orindi, Seydou Sawadogo, Sean C. Elias, Karim Derra, D Bellamy, Faizatou Sorgho, Magloire H Natama, Adrian V. S. Hill, E Mukhopadhyay, Hermann Sorgho, Innocent Valea, Alison M. Lawrie, Moubarak Tegneri, Rachel Roberts, Gregory M. Glenn, Halidou Tinto, Louis Fries, Nicola Williams
Publikováno v:
Lancet, 397 (10287
Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 12 months in African children.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8ce074b426a190ef5d943b4c759db00
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/323431
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/323431
Autor:
Michael Theisen, Bishwanath Kumar Chourasia, Jordan Plieskatt, Karin Lövgren Bengtsson, Geert-Jan van Gemert, Matthijs M. Jore, Vandana Singh, Marga van de Vegte-Bolmer, Karina Teelen, Susheel K. Singh, Jenny M. Reimer, Renate C van Daalen
Publikováno v:
Npj Vaccines, 6, 1
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
Npj Vaccines, 6
NPJ Vaccines
Singh, S K, Plieskatt, J, Chourasia, B K, Singh, V, Bengtsson, K L, Reimer, J M, van Daalen, R C, Teelen, K, van de Vegte-Bolmer, M, van Gemert, G-J, Jore, M M & Theisen, M 2021, ' Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine ', npj Vaccines, vol. 6, 120 . https://doi.org/10.1038/s41541-021-00383-8
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
Npj Vaccines, 6
NPJ Vaccines
Singh, S K, Plieskatt, J, Chourasia, B K, Singh, V, Bengtsson, K L, Reimer, J M, van Daalen, R C, Teelen, K, van de Vegte-Bolmer, M, van Gemert, G-J, Jore, M M & Theisen, M 2021, ' Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine ', npj Vaccines, vol. 6, 120 . https://doi.org/10.1038/s41541-021-00383-8
The Plasmodium falciparum Pfs230 and Pfs48/45 proteins are leading candidates for a malaria transmission-blocking vaccine (TBV). Previously, we showed that a Pfs230–Pfs48/45 fusion protein elicits higher levels of functional antibodies than the ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025a76d3d869cfa92d79be67006b205c
https://repository.ubn.ru.nl/handle/2066/239289
https://repository.ubn.ru.nl/handle/2066/239289